A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

NCT00320255 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Thrombosis
Cancer
Pulmonary Embolism

Interventions

DRUG: Apixaban
DRUG: Placebo

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]